NCT07844512
Safety and Analgesic Efficacy of the Biased μ-Opioid Receptor Agonist Tegileridine for Post-Operative Analgesia in Patients Undergoing Bariatric Surgery
StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 2 with changes below, 1 re-verified with no change.
- Notable Recruitment opened
- Start date changed from estimate of Oct 1, 2026 to Oct 28, 2026
- Study sites: 0 to 1
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Quality of Recovery-15 (QoR-15) Score at 24 Hours After Surgery
Timeframe: 24 hours after bariatric surgery
Arms and interventions
Tegileridine GroupExperimental
Standard Opioid GroupActive comparator
Drugs: Tegileridine (tegileridine fumarate injection, IV), Sufentanil
Sites
1 site in 1 country
- The First Hospital of Jilin UniversityChangchun, Jilin, China